Catalyst Wire Dossier Catalyst Wire Dossier

PF Ophthalmic Solution containing Hyaluronic Acid 0.4% and TAU 0.5%

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PF Ophthalmic Solution containing Hyaluronic Acid 0.4% and TAU 0.5%, covering 2018-03-29 to 2018-03-29. Get the full timeline:

Most recent: Clinical Trial Update: Effects of a PF Ophthalmic Solution Containing HA0.4% and TAU 0.5% [NA]

See pricing